HAB Pharma, Signature Phytochemicals merge to form Rs. 600 crore integrated pharma entity
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Subscribe To Our Newsletter & Stay Updated